Aerska, which uses brain shuttle technology to deliver RNAi therapeutics to the brain, announced the close of a $39 million Series A financing round, bringing its total funding to $60 million. EQT ...

Scientists have spent decades trying to get medicine across the blood-brain barrier. Two treatments for a rare genetic ...

Brain shuttle technology is entering a new phase. A year after BioCentury mapped a field led by protein therapeutics, much of ...

DUBLIN and LONDON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a $39 ...

Alzheimer’s disease can be treated with antibodies that clear away plaques of amyloid protein, but these medicines require frequent dosing and they introduce serious safety risks. Korsana Biosciences ...

The blood–brain barrier (BBB) is a protective filter that lines the brain's blood vessels and is notoriously hard to penetrate, making the treatment of brain disorders very difficult. Strategies ...

Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...

Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery using direct-to-vivo measurement, announced a major research collaboration and license agreement with Roche to develop ...

Newswise — Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the ...

The highly selective border lining the brain’s vasculature is the Achilles’ heel of any large therapeutic molecule aiming for targets in the brain, anti-Aβ antibodies included. Not only do fewer than ...